Oncological Outcomes From Trimodality Therapy Receiving Definitive Doses of Neoadjuvant Chemoradiation (≥60 Gy) and Factors Influencing Consideration for Surgery in Stage III Non-Small Cell Lung Cancer
Advances in Radiation Oncology - United States
doi 10.1016/j.adro.2017.07.009
Full Text
Open PDFAbstract
Available in full text
Date
July 1, 2017
Authors
Publisher
Elsevier BV